Use of Antiepileptic Drugs for Nonepileptic Conditions: Psychiatric Disorders and Chronic Pain

Neurotherapeutics

Volumn 4, Issue 1, 2007, Pages 75-83

  Ettinger, Alan B ^a   Argoff, Charles E ^a  

^a North Shore Long Island Jewish Health System ^*  (United States)

Author keywords

antiepileptic drugs; anxiety; depression; migraine; neuropathic pain; pain; psychosis; Psychotropic properties

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; OXCARBAZEPINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PLACEBO; PREGABALIN; TIAGABINE; TIZANIDINE; TOCAINIDE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ADD ON THERAPY; AGGRESSION; AGGRESSIVENESS; AGNOSIA; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; AUDITORY HALLUCINATION; BIPOLAR DISORDER; BLOOD TOXICITY; BRAIN DISEASE; CHRONIC PAIN; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CLUSTER HEADACHE; COGNITIVE DEFECT; COMPLEX REGIONAL PAIN SYNDROME; COUGHING; DELUSION; DEMENTIA; DEPRESSION; DIABETIC NEUROPATHY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EPILEPSY; EPILEPTIC STATE; HAMILTON SCALE; HOARSENESS; HUMAN; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MENTAL HEALTH; MIGRAINE; MOOD DISORDER; NECK PAIN; NEUROPATHIC PAIN; NONHUMAN; PANIC; PARANOIA; POSTHERPETIC NEURALGIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RADICULOPATHY; RAPID CYCLING BIPOLAR DISORDER; RESTLESSNESS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOCIAL PHOBIA; SPINAL CORD INJURY; SUSTAINED DRUG RELEASE; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION; VISUAL HALLUCINATION; VOICE CHANGE; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ANTICONVULSANTS; BRAIN; CHRONIC DISEASE; CLINICAL TRIALS; HUMANS; MENTAL DISORDERS; PAIN;

EID: 33846317797     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2006.10.003     Document Type: Article

References (122)

1. Ballenger J.C., and Post R.M. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 137 (1980) 782-790
2. Goodnick P.J. Anticonvulsants in the treatment of bipolar mania. Expert Opin Pharmacother 7 (2006) 401-410
3. Rush A.J., Fava M., Wisniewski S.R., et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25 (2004) 119-142
4. Rush A.J., Trivedi M., and Fava M. Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry 160 (2003) 237
5. Swartz M.S., Perkins D.O., Stroup T.S., McEvoy J.P., Nieri J.M., and Haak D.C. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull 29 (2003) 33-43
6. Toczek M.T., Carson R.E., Lang L., et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 60 (2003) 749-756
7. Sargent P.A., Kjaer K.H., Bench C.J., et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57 (2000) 174-180
8. Dailey J.W., Reither M.E.A., Yan Q.S., Li M.Y., and Jobe P.C. Anticonvulsant doses of carbamazepine increase hippocampal extracellular serotonin in genetically epilepsy-prone rats: dose response relationships. Neurosci Lett 226 (1997) 13-16
9. Southam E., Kirkby D., Higgins G.A., and Hagan R.M. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol 358 (1998) 19-24
10. Whitton P.S., and Fowler L.J. The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur J Pharmacol 200 (1991) 167-169
11. Yan Q.S., Mishra P.K., Burger R.L., Bettendorf A.F., Jobe P.C., and Dailey J.W. Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. J Pharmacol Exp Ther 261 (1992) 652-659
12. Naritoku D.K., Terry W.J., and Helfert R.H. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res 22 (1995) 53-62
13. Browning R.A., Clark K.B., Naritoku D.K., Smith D.C., and Jenson R.A. Loss of anticonvulsant effect of vagus nerve stimulation in the pentylenetetrazol seizure model following treatment with 6-hydroxydopamine or 5,7-dihyrdroxy-tryptamine. Soc Neurosci 23 (1997) 2424
14. Nahas Z., Marangell L.B., Husain M.M., et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 66 (2005) 1097-1104
15. Reynolds E.H., and Trimble M.R. Adverse neuropsychiatric effects of anticonvulsant drugs. Pharmacol Biochem Behav 23 (1985) 21-26
16. Hauser P., Devinsky O., DeBellis M., et al. Benzodiazepine withdrawal delirium with catatonic features. Arch Neurol 46 (1989) 696-699
17. Bowden C.L., Calabrese J.R., McElroy S.L., et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57 (2000) 481-489
18. Findling R.L., McNamara N.K., Youngstrom E.A., et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 44 (2005) 409-417
19. Winsberg M.E., DeGolia S.G., Strong C.M., and Ketter T.A. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 67 (2001) 207-212
20. Porsteinsson A.P., Tariot P.N., Erb R., et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 9 (2001) 58-66
21. Sival R.C., Haffmans P.M., Jansen P.A., Duursma S.A., and Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 17 (2002) 579-585
22. Hollander E., Tracy K.A., Swann A.C., et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 28 (2003) 1186-1197
23. Baetz M., and Bowen R.C. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 43 (1998) 73-77
24. Woodman C.L., and Noyes Jr. R. Panic disorder: treatment with valproate. J Clin Psychiatry 55 (1994) 134-136
25. Mishory A., Yaroslavsky Y., Bersudsky Y., and Belmaker R.H. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 157 (2000) 463-465
26. Mishory A., Winokur M., and Bersudsky Y. Prophylactic effect of phenytoin in bipolar disorder: a controlled study. Bipolar Disord 5 (2003) 464-467
27. Nemets B., Bersudsky Y., and Belmaker R.H. Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. J Clin Psychiatry 66 (2005) 586-590
28. Stanford M.S., Helfritz L.E., Conklin S.M., et al. A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol 13 (2005) 72-77
29. Kowatch R.A., Suppes T., Carmody T.J., et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 39 (2000) 713-720
30. Ketter T.A., Kalali A.H., and Weisler R.H. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 65 (2004) 668-673
31. Gajwani P., Forsthoff A., Muzina D., et al. Antiepileptic drugs in mood-disordered patients. Epilepsia 46 suppl 4 (2005) 38-44
32. Greil W., Kleindienst N., Erazo N., and Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 18 (1998) 455-460
33. Hartong E.G., Moleman P., Hoogduin C.A., Broekman T.G., and Nolen W.A. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 64 (2003) 144-151
34. Weisler R.H., Kalali A.H., and Ketter T.A. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 65 (2004) 478-484
35. Weisler R.H., Keck Jr. P.E., Swann A.C., Cutler A.J., Ketter T.A., and Kalali A.H. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 66 (2005) 323-330
36. Ettinger A.B., Bernal O.G., Andriola M.R., et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 40 (1999) 1159-1162
37. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 64 (2003) 1245-1249
38. Suppes T., Chisholm K.A., Dhavale D., et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 4 (2002) 283-289
39. Grunze H., Erfurth A., Marcuse A., Amann B., Normann C., and Walden J. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 60 (1999) 759-762
40. Pande A.C., Davidson J.R.T., Jefferson J.W., et al. Treatment of social phobia with gabapentin: a placebo controlled study. J Clin Psychopharmacol 19 (1999) 341-348
41. Chouinard G., Beauclair L., and Belanger M.-C. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry 43; (1998) 305
42. Chatterjee C.R., and Ringold A.L. A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin. J Clin Psychiatry 60 (1999) 617
43. Mariani J.J., Rosenthal R.N., Tross S., Singh P., and Anand O.P. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict 15 (2006) 76-84
44. Moretti R., Torre P., Antonello R.M., Cazzato G., and Bava A. Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation. Drugs Aging 20 (2003) 1035-1040
45. Rickels K., Pollack M.H., Feltner D.E., et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62 (2005) 1022-1030
46. Pohl R.B., Feltner D.E., Fieve R.R., and Pande A.C. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 25 (2005) 151-158
47. Calabrese J.R., Bowden C.L., Sachs G.S., et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 60 (1999) 79-88
48. McElroy S.L., Zarate C.A., Cookson J., et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 65 (2004) 204-210
49. Calabrese J.R., Bowden C.L., Sachs G., et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64 (2003) 1013-1024
50. Bowden C.L., Calabrese J.R., Sachs G., et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60 (2003) 392-400
51. Gates J.R., Folland C., Ankenbauer J.L., Moriarty G.L., and Penovich P.E. Behavioral side effects of levetiracetam. Epilepsia 43 suppl 7 (2002) 187
52. McBride A.E., Perrine K.R., Gunning-Dixon F.M., Hamann J., Risbrook D.N., and Ettinger A.B. Positive psychotropic effects associated with the use of lamotrigine in a clinical setting. Epilepsia 43 suppl 7 (2002) 95-96
53. Mula M., Trimble M.R., Yuen A., Liu R.S.N., and Sander J.W.A.S. Psychiatric adverse events during levetiracetam therapy. Neurology 61 (2003) 704-706
54. Kossoff E.H., Bergey G.K., Freeman J.M., and Vining E.P. Levetiracetam psychosis in children with epilepsy. Epilepsia 42 (2001) 1611-1613
55. Bersani G. Levetiracetam in bipolar spectrum disorders: first evidence of efficacy in an open, add-on study. Hum Psychopharmacol 19 (2004) 355-356
56. Grunze H., Langosch J., Born C., Schaub G., and Walden J. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 64 (2003) 781-784
57. Simon N.M., Worthington J.J., Doyle A.C., et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 65 (2004) 1219-1222
58. McElroy S.L., Suppes T., Keck Jr. P.E., et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry 66 (2005) 617-624
59. Anand A., Bukhari L., Jennings S.A., et al. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. J Clin Psychiatry 66 (2005) 195-198
60. Spina E., and Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 6 (2004) 57-75
61. Benedetti A., Lattanzi L., Pini S., Musetti L., Dell'Osso L., and Cassano G.B. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 79 (2004) 273-277
62. Hummel B., Walden J., Stampfer R., et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord 4 (2002) 412-417
63. Bahk W.M., Shin Y.C., Woo J.M., et al. Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 115-121
64. Chengappa K.N., Rathore D., Levine J., et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1 (1999) 42-53
65. McElroy S.L., Suppes T., Keck P.E., et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 47 (2000) 1025-1033
66. McIntyre R.S., Mancini D.A., McCann S., Srinivasan J., Sagman D., and Kennedy S.H. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 4 (2002) 207-213
67. Kamini V., Karine M., John G., Stuart W., and Allan Y. Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev (2006) CD003384
68. Dursun S.M., and Devarajan S. Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action?. Can J Psychiatry 46 (2001) 287-288
69. Kanner A.M., Wuu J., Faught E., Tatum W.O., Fix A., and French J.A. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4 (2003) 548-552
70. Reith D., Burke C., Appleton D.B., Wallace G., and Pelekanos J. Tolerability of topiramate in children and adolescents. J Paediatr Child Health 39 (2003) 416-419
71. Kober D., and Gabbard G.O. Topiramate-induced psychosis. Am J Psychiatry 162 (2005) 1542
72. Stella F., Caetano D., Cendes F., and Guerreiro C.A. Acute psychotic disorders induced by topiramate: report of two cases. Arq Neuropsiquiatr 60 (2002) 285-287
73. Besag F.M. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf 3 (2004) 1-8
74. Hofer A., Fleischhacker W.W., and Hummer M. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. J Clin Psychiatry 64 (2003) 1267-1268
75. Duggal H.S., and Singh I. Worsening of psychosis or topiramate-induced adverse event?. Gen Hosp Psychiatry 26 (2004) 245-247
76. Nickel M.K., Nickel C., Mitterlehner F.O., et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 65 (2004) 1515-1519
77. Nickel M.K., Nickel C., Kaplan P., et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 57 (2005) 495-499
78. Janowsky D.S., Kraus J.E., Barnhill J., Elamir B., and Davis J.M. Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled: an open-label retrospective study. J Clin Psychopharmacol 23 (2003) 500-504
79. Berlant J.L. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 4 (2004) 24
80. Rush A.J., George M.S., Sackeim H.A., et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: a multicenter study. Biol Psychiatry 47 (2000) 276-286
81. George M.S., Rush A.J., Marangell L.B., et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 58 (2005) 364-373
82. Backonja M.M. Use of anticonvulsants for treatment of neuropathic pain. Neurology 59 suppl 2 (2002) S14-S17
83. Dworkin R.H., Corbin A.E., Young Jr. J.P., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60 (2003) 1274-1283
84. Sabatowski R., Galvez R., Cherry D.A., et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized, placebo-controlled trial. Pain 109 (2004) 26-35
85. Rosenstock J., Tuchman M., LaMoreaux L., et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110 (2004) 628-638
86. Lesser H., Sharma U., LaMoreaux L., et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63 (2004) 2104-2110
87. Richter R.W., Portenoy R., Sharma U., et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6 (2005) 253-260
88. Van Seventer R., Feister H.A., Young Jr. J.P., et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week randomized trial. Curr Med Res Opin 22 (2006) 375-384
89. Crofford L.J., Rowbotham M.C., Mease P.J., et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 1264-1273
90. Rice A.S., Maton S., and Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double-blind, placebo-controlled study. Pain 94 (2001) 215-224
91. Rowbotham M., Harden N., Stacey B., et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280 (1998) 1837-1842
92. Backonja M., Beydound A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 (1998) 1831-1836
93. Gilron I., and Flatters S.J. Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. Pain Res Manag 11 suppl A (2006) 16A-29A
94. Smith D.G., Ehde D.M., Hanley M.A., et al. Efficacy of gabapentin in treating chronic phantom limb and residual limb pain. J Rehabil Res Dev 42 (2005) 645-654
95. Mathew N.T., Rapoport A., Saper J., et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41 (2001) 119-128
96. Dirks J., Fredensborg B.B., Christensen D., Fomsgaard J.S., Flyger H., and Dahl J.B. A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy. Anesthesiology 97 (2002) 560-564
97. Killian J.M., and Fromm G.H. Carbamazepine in the treatment of neuralgia. Use and side effects. Arch Neurol 19 (1968) 129-136
98. Nicol C.F. A four year double blind study of Tegretol in facial pain. Headache 9 (1969) 54-57
99. Vilming S.T., Lyberg T., and Lataste X. Tizanidine in the management of trigeminal neuralgia. Cephalgia 6 (1986) 181-182
100. Lindsrom P., and Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 28 (1987) 45-50
101. Lechin F., van der Dijs B., Lechin M.E., et al. Pimozide therapy for trigeminal neuralgia. Arch Neurol 46 (1989) 960-963
102. Rull J., Quibrera R., Gonzalez-Millan H., et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double-blind crossover study. Diabetologia 5 (1969) 215-220
103. Leijon G., and Boivie J. Central post-stroke pain- a controlled trial of amitriptyline and carbamazepine. Pain 28 (1989) 45-50
104. Silberstein S.D. Topiramate in migraine prevention. Headache 45 suppl 1 (2005) S57-S65
105. Mathew N.T., Kailasam J., and Meadors L. Prophylaxis of migraine, transformed migraine and cluster headache with topiramate. Headache 42 (2002) 796-803
106. Chong M.S., and Libretto S.E. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain 19 (2003) 59-68
107. Thienel U., Neto W., Schwabe S.K., et al. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo controlled trials. Acta Neurol Scand 10 (2004) 221-231
108. Raskin P., Donofrio P.D., Rosenthal N., et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 63 (2004) 865-873
109. Khoromi S., Patsalides A., Parada S., et al. Topiramate in chronic lumbar radicular pain. J Pain 6 (2005) 829-836
110. Muehlbacher M., Nickel M.K., Kettler C., et al. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain 22 (2006) 526-531
111. Rothrock J.F. Clinical studies of valproate for migraine prophylaxis. Cephalalgia 17 (1997) 81-83
112. Chadda V.S., and Mathur M. Double-blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicans India 26 (1978) 403-406
113. Saudek C.D., Werns S., and Reidenberg M.M. Phenytoin in the treatment of diabetic symmetrical neuropathy. Clin Pharmacol Ther 22 (1977) 196-199
114. McCleane G.J. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blind, placebo-controlled, crossover study. Anesth Analg 89 (1999) 985-988
115. Vestergaard K., Andersen G., Gottrup H., et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 56 (2001) 184-190
116. Simpson D.M., McArthur J.C., Olney R., et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 60 (2003) 1508-1514
117. Zakrzewska J.M., Chaudhry Z., Nurmikko T.J., et al. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo-controlled crossover trial. Pain 73 (1997) 223-230
118. Sindrup S.H., and Jensen T.S. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 18 (2002) 22-27
119. Finnerup N.B., Sindrup S.H., Bach F.W., et al. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 96 (2002) 375-383
120. McCleane G. 200mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomized, double-blind placebo controlled trial. Pain 83 (1999) 105-107
121. Zakrzewska J.M., and Pansalos P.N. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J Neurol Neurosurg Psychiatry 52 (1989) 472-476
122. Dogra S., Beydoun S., Mazzola J., et al. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain 9 (2005) 543-554